The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.
Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.
Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.
Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates ...
Inocras has entered a strategic partnership with AimedBio to enhance cancer drug development using whole genome intelligence.
In Sanofi's Baby-COMET trial, Nexviazyme met all primary and secondary endpoints, teeing it up for potential label expansion in Pompe disease.
The retraction further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results